Milli-Mark Anti-CD27-FITC

Code: FCMAB191F D2-231

Analysis Note

ControlPBMCs

Application

Research Sub CategoryImmunoglobulins & Immunology

This Milli-Mark Anti-CD27-FITC Antibody, clone M-T...


read more

Your Price
€414.00 EACH
€509.22 inc. VAT

Analysis Note

ControlPBMCs

Application

Research Sub CategoryImmunoglobulins & Immunology

This Milli-Mark Anti-CD27-FITC Antibody, clone M-T271 is validated for use in FC for the detection of CD27.

Research CategoryInflammation & Immunology

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

CD27, a member of the nerve growth factor receptor (NGFR) superfamily, is a type I transmembrane protein consisting of a disulphide-linked 120 kDa homodimer (Bigler, 1988; Sugita, 1992; Morimoto, 1995). CD27 is expressed on mature thymocytes and on the majority of human peripheral blood T cells, on both CD4+ and CD8+ subsets. CD27 is also expressed on activated B cells and a fraction of resting natural killer (NK) cells (Maurer, 1990; Sugita, 1992). Among CD4+ T cells, CD27 is preferentially expressed on unprimed CD4+CD45RA+CD45R0- T cells, while primed CD4+CD45RA-CD45R0+ T cells express low levels of CD27 (Sugita, 1992). During activation, the expression of CD27 is increased on B cells and unprimed T cells, while primed T cells have a relatively low capacity for upregulation of CD27 (Morimoto, 1995; Hintzen, 1994). The activation is also accompanied by the appearance of a 32 kDa soluble form of CD27 (sCD27) found in supernatants of activated lymphocytes (Hintzen, 1994).
CD27 is believed to play a role in T cell activation, since the expression is upregulated during T cell activation (Bigler, 1988; Sugita, 1992; Morimoto, 1995; Maurer, 1990; Hintzen, 1994; Lens, 1995).

Immunogen

Leukemic peripheral blood T cells from a patient with chronic T cell leukemia (T-CLL)

Legal Information

MILLI-MARK is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Physical form

Protein A purified

Purified Mouse monoclonal IgG1 conjugated to FITC in 0.05M Tris-HCl buffer with 1% BSA, Sodium Azide at 0.097% at pH 7.2.

Quality

Evaluated by flow cytometry using human PBMCs

Specificity

Antibody recognizes Human CD27 antigen.

Storage and Stability

Maintained refrigerated at 2-8°C from date of receipt. Protected from light in undiluted aliquots for 6 months from date of receipt.

Target description

120 kDa (Bigler, 1988; Sugita, 1992; Morimoto, 1995)

antibody formpurified antibody
antibody product typeprimary antibodies
biological sourcemouse
cloneM-T271, monoclonal
conjugateFITC conjugate
Gene Informationhuman ... CD27(939)
isotypeIgG1κ
manufacturer/tradenameMilli-Mark®
NCBI accession no.NP_001233.1
Quality Level100
shipped inwet ice
species reactivityhuman
technique(s)flow cytometry: suitable
UniProt accession no.P26842
This product has met the following criteria to qualify for the following awards:



PROCEED TO CHECKOUT

HAVE AN ACCOUNT? LOGIN


GUEST CHECKOUT

Proceed as a guest. You will have the option to register to access exclusive pricing and stock availability features after checkout.